Navigation Links
BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
Date:11/5/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York.

WHEN: Monday November 10th at 12:00pm (Eastern Time)

WHERE: New York Palace Hotel, New York.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, th
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
2. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
3. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
4. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
5. BioMS Medical to present at UBS Global Life Sciences Conference
6. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
7. BioMS Medical announces its intention to renew a normal course issuer bid
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. BioMS Medical Announces Second Quarter 2008 Results
10. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
11. BioMS Medical to present at BMO Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015   Tocagen Inc. , a clinical-stage ... Parkinson , M.D., a venture partner at New ... board of directors of Tocagen. Dr. Parkinson has ... clinical development, including leading clinical activities at Amgen ... the cancer therapeutics Gleevec®, Femara®, Zometa®, Kepivance® and ...
(Date:5/5/2015)... 5, 2015  Indianapolis-based medical device manufacturer NICO ... line of products including the BrainPath® and Myriad™ ... deep-seated brain abnormalities and then removing affected tissue. ... more than 50 institutions throughout the ... been included in 12 abstracts, three peer-reviewed publications, ...
(Date:5/4/2015)... 4, 2015 Many of us take ... certain infants with rare, inherited mutations of certain ... of their impaired immune responses. Now, ... an important role for calcium signaling in immune ... the bacterium causing tuberculosis (TB). ...
(Date:5/4/2015)... 2015   St. Jude Children,s Research Hospital ... tool for finding genetic alterations that play an ... to identify with whole-genome sequencing. The findings appear ... . The tool is an algorithm ... Regression Tree in Next Generation Sequencing. ...
Breaking Biology Technology:Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4
... Will Increase Productivity to Meet Growing Global Demand , ... Jakarta, Indonesia ... Center for Rice Research (ICRR) today announced an agreement that grants ... rice hybrids in Asia. , , , , ,Rice is the most ...
... world,s first omega-3 enhanced water is available for ... Zymes Omega Solutions, Inc., an affiliate of Zymes ... the world,s first omega-3 enhanced water, OmegaChill ... water uses Zymes, PTS technology to solubilize and ...
... Helix BioPharma Corp. (TSX, FSE: "HBP") announced that ... Germany to initiate its planned Phase II pharmacokinetic ... low-grade cervical lesions.The clinical study was designed, as ... the absorption and elimination profile of Topical Interferon ...
Cached Biology Technology:DuPont Partners with Indonesian Center for Rice Research to Advance Hybrid Rice 2DuPont Partners with Indonesian Center for Rice Research to Advance Hybrid Rice 3Zymes Omega Solutions Bottles and Launches the World's First Omega-3 Enhanced Water 2Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 2Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 3Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 4Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 5
(Date:3/30/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) ... Recognition Market in Automotive Sector 2014-2018" report to ... Gesture Recognition market in Automotive Sector to grow at ... Gesture recognition is the ability of a device ... individual. Gesture recognition technology can be 2D-based or 3D-based. ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
(Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... award in the "commercial" category of Illumina,s Data Excellence ... of. iDEA is Illumina,s program designed to challenge the ... data analysis techniques. "The iDEA challenge really sparked ... about it. Genomatix is a scientific company at heart, ...
... Today someone in a remote village in India is ... on a loved one having a potential heart attack and ... Mobile technology is already bringing health care to places ... still room for error that can lead to misdiagnosis. ...
... University] All the excitement about nanotechnology comes down ... billionths of a meter take on unusual properties. Technologists ... but new research by an interdisciplinary team of scientists ... a cellular pathway that contributes to cancer in human ...
Cached Biology News:UT researchers develop algorithm to improve remote electrocardiography 2Nickel nanoparticles may contribute to lung cancer 2
Mouse monoclonal [SH-A1] to S100 alpha ( Abpromise for all tested applications). entrezGeneID: 6271 SwissProtID: P23297...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: